Bayer Menopause Drug Receives FDA Approval
Bayer's Lynkuet, a once-daily pill, has been approved for treating moderate-to-severe vasomotor symptoms of menopause.
The drug targets two receptors key to temperature regulation and came from Bayer's 2020 acquisition of KaNDy Therapeutics.
Elinzanetant, a small molecule formulated as a soft gel capsule, will be commercialized under the brand name Lynkuet and offers a new non-hormonal therapeutic option.
Hormone therapies, a standard treatment for menopause symptoms, can raise the risk of cardiovascular complications, making non-hormonal options necessary for women with heart issues.
The Bayer drug may have an advantage over an Astellas Pharma product that has a two-year head start in this market.
Author's summary: Bayer's Lynkuet approved for menopause symptoms.
More News
- New president of The Church of Jesus Christ of Latter-day Saints inherits a global faith far more diverse than many realize – Baptist News Global
- Election Guide 2025: Nassau County Legislature District 7 candidate Alec Fischthal, Dem.
- Art the Clown Owes One of His 'Terrifier' Actresses a Lot of Money
- Elon Musk Unveils Grokipedia - IT News Africa | Business Technology, Telecoms and Startup News
- NGP-backed Cygnet Energy to buy Kiwetinohk Energy for $1bn | PE Hub
- Redefining surgical access: How ASCs transform the healthcare ecosystem - Becker’s ASC
- Andreas Kaufer appointed as next ESO Director General
- Manhattan Associates Achieves FedRAMP Authorization with FEMA, Expanding Secure Cloud Offerings for Government Agencies
- Member Day 2026 - Save the Date - Somerset
- AIs Capture Trust Cues – Communications of the ACM